KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies. (PubMed, Front Oncol) - Sep 9, 2026 - "The recent approval of covalent KRAS G12C inhibitors, sotorasib and adagrasib, has revealed that targeted KRAS blockade can remodel the TME toward an immunostimulatory state, providing a mechanistic rationale for combining KRAS-directed agents with immune checkpoint blockade, STING agonists, and neoantigen vaccines. This mini-review synthesizes the current knowledge of KRAS-immune crosstalk, highlights existing controversies and research gaps, and evaluates emerging combination strategies designed to convert immune exclusion into durable anti-tumor immunity."
IO biomarker • Journal • Review • Colorectal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KEAP1 • KRAS • PI3K • STK11 • TP53
|
|
Haily Liduin Koyou; Liyana Najwa Binti Inche Mat; Mohd Hazmi Bin Mohamed; Mohd Nazil Salleh; Muhammad Evy Prastiyanto; Nurul Aini Binti Ahmad; Siddarth Raajasekar; Vasudevan Ramachandran; Venkataramanan Swaminathan
|